Would you continue immune checkpoint inhibitor therapy in a metastatic NSCLC patient with CNS failure if the systemic disease is otherwise controlled?

Does the extent/duration of systemic disease control (complete response vs. stable disease, for example) influence your decision? What about whether this is in the first-line vs. 2nd/3rd-line setting?

Answer from: Medical Oncologist at Academic Institution

Great question with limited data to give a "correct answer." I have seen CNS response to checkpoint inhibitors, but I do not expect CNS response from it. In my practice, if I saw truly isolated CNS failure with good systemic control, I would continue checkpoint inhbibitory therapy as lon...

Comments

Medical Oncologist at Virginia Cancer Institute
Do you employ this strategy regardless of the pati...

Medical Oncologist at University of North Carolina School of Medicine
In terms of how I consider intracarnial vs. system...

Please select the option that best describes you:

Would you continue immune checkpoint inhibitor therapy in a metastatic NSCLC patient with CNS failure if the systemic disease is otherwise controlled?

Related Questions